

GenVec

[View the current GenVec Page on BioPortfolio.com](http://www.bioportfolio.com)

(<http://www.bioportfolio.com/biocorporate/534-GenVec.html>)

Contact Details:

**65 West Watkins Mill Road
Gaithersburg
Maryland
20878
United States of America**

Tel: (240) 632-0740 or (877) 943-6832

Fax: (240) 632-0735

Email: resume@genvec.com

GenVec, Inc. (NASDAQ: GNVC) is a biopharmaceutical company developing novel gene-based therapeutic drugs and vaccines. Each of our gene-based therapeutic product candidates use a common patent-protected technology platform to deliver genes that produce medically beneficial proteins directly at the site of disease. TNFerade™ represents a novel approach to treating cancer in combination with radiation and/or chemotherapy by introducing tumor necrosis factor-alpha (TNF-alpha), a potent anti-cancer protein, directly into tumors. Pancreatic cancer is the lead indication for TNFerade™. We are conducting a 330-patient randomized, controlled Phase II/III clinical trial designed to assess the safety and clinical benefit of using TNFerade™ in combination with standard of care treatment in patients with locally advanced pancreatic cancer. Phase II trials in rectal cancer and melanoma are also ongoing. AdPEDF is being developed for patients with wet age-related macular degeneration (AMD) to determine whether pigment epithelium-derived factor (PEDF) prevents vision loss in this leading cause of blindness in people over the age of 50. We have completed a Phase I clinical trial of PEDF in patients with severe AMD. Data from this trial demonstrated that PEDF was generally well tolerated with no dose limiting toxicities. Expanded clinical testing of PEDF in AMD patients with less severe disease is ongoing. TherAtoh Atonal Therapy is a product concept to restore hearing or balance function through the regeneration of critical cells of the inner ear. Hearing and Balance require specialized cells of the inner ear called sensory hair cells. During embryonic development a gene termed atonal (ATOH) induces the generation of these cells. GenVec has shown preclinically that the production of the ATOH protein results in the formation of new inner ear sensory hair cells, and the restoration of hearing and balance function. TherAtoh is an adenovector product delivering the human atonal gene (Hath1) to trigger the production of therapeutic proteins by cells in the inner ear. We also are using GenVec's proprietary adenovector technology to develop vaccines for infectious diseases. Worldwide HIV vaccine in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) Malaria vaccine in collaboration with U.S. Navy and PATH's Malaria Vaccine Initiative Foot and Mouth Disease antiviral and vaccine program in collaboration with the United States Department of Agriculture/Agricultural Research Services (USDA-ARS) Seasonal and pandemic influenza vaccines in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) GenVec, Inc. is based in Gaithersburg, Maryland. GenVec, Inc. is based in Gaithersburg, Maryland.

- [Differential specificity and immunogenicity of adenovirus 5 neutralizing antibodies elicited by natural infection or immunization.](#)
A recent clinical trial of a T-cell-based AIDS vaccine delivered with... 23rd October, 2009
Vaccine Research Center, NIAID, National Institutes of Health, Bldg. 40,- J Virol. 2009 Oct 21. ([DOI Direct Link](#))
- [Combination of human tumor necrosis factor-alpha \(hTNF-alpha\) gene delivery with gemcitabine is effective in models of pancreatic cancer.](#)
Pancreatic adenocarcinoma is an aggressive and highly lethal malignancy.... 16th May, 2009
Department of Research, GenVec Inc, Gaithersburg, MD 20878, USA.- Cancer Gene Ther. 2009 Nov;16(11):841-7. Epub 2009 May 15. ([DOI Direct Link](#))
- [Alternate serotype adenovector provides long-term therapeutic gene expression in the eye.](#)
PURPOSE: To determine whether the duration of transgene expression from an... 2nd April, 2009
Pre-Clinical Sciences, GenVec Inc, Gaithersburg, MD 20878, USA.- Mol Vis. 2008;14:2535-46. Epub 2008 Dec 30.
- [Repeat administration of proteins to the eye with a single intraocular injection of an adenovirus vector.](#)
Delivery of therapeutic proteins, such as antiangiogenic proteins, to the... 23rd January, 2009
Vector Sciences, GenVec, Inc., Gaithersburg, Maryland, USA.- Mol Ther. 2008 Aug;16(8):1444-9. Epub 2008 Jun 10. ([DOI Direct Link](#))
- [Persistent expression of PEDF in the eye using high-capacity adenovectors.](#)
Ocular neovascularization, the growth of abnormal blood vessels in the... 8th January, 2009
GenVec, Inc. Research Department, Gaithersburg, Maryland 20878, USA.- Mol Ther. 2008 Dec;16(12):1986-94. Epub 2008 Sep 30. ([DOI Direct Link](#))
- [Promoters influence the kinetics of transgene expression following adenovector gene delivery.](#)
BACKGROUND: The kinetics of gene expression from adenovirus-based delivery... 19th April, 2008
GenVec, Inc., 65 West Watkins Mill Road, Gaithersburg, MD 20878, USA.- J Gene Med. 2008 Feb;10(2):123-31. ([DOI Direct Link](#))
- [Local gene delivery of tumor necrosis factor alpha can impact primary tumor growth and metastases through a host-mediated response.](#)
TNFerade is a replication incompetent adenovector designed to express... 4th January, 2008
GenVec, Inc., 65 W. Watkins Mill Road, Gaithersburg, MD 20878, USA.- Clin Exp Metastasis. 2007;24(7):521-31. Epub 2007 Jul 25. ([DOI Direct Link](#))
- [Experimental treatment of ovarian cancers by adenovirus vectors combining receptor targeting and selective expression of tumor necrosis factor.](#)
Ovarian cancer is the fourth most common cancer among women and existing... 9th November, 2007
GenVec Inc, Gaithersburg, Gaithersburg, MD 20878, USA.- Int J Oncol. 2007 Oct;31(4):813-22.
- [Rescue and production of vaccine and therapeutic adenovirus vectors expressing inhibitory transgenes.](#)
Expression of certain transgenes from an adenovirus vector can be... 18th September, 2007
GenVec, Inc. 65 West Watkins Mill Rd, Gaithersburg MD 20878, USA.- Mol Biotechnol. 2007 Mar;35(3):263-73.
- [Comprehensive characterization of the 293-ORF6 cell line.](#)
Expression of certain transgenes from an adenovirus vector can be... 4th May, 2006
GenVec, Inc.,- Dev Biol (Basel). 2006;123:225-33; discussion 265-6.
- [Adenovector pigment epithelium-derived factor \(AdPEDF\) delivery for wet age-related macular degeneration.](#)
PURPOSE: To determine whether repeat administration of an adenovector (Ad)... 2nd March, 2006
Preclinical Sciences in the Department of Research at GenVec, Inc.- Retina. 2005 Dec;25(8)

Suppl):S48-S49.

- [Repeated administration of adenovector in the eye results in efficient gene delivery.](#)
*PURPOSE: To determine whether repeat administration of an adenovector (Ad)...*10th February, 2006
GenVec, Inc., Gaithersburg, Maryland 20878, USA.- Invest Ophthalmol Vis Sci. 2006
Jan;47(1):299-305. ([DOI Direct Link](#))
- [Adenovirus vector library: an approach to the discovery of gene and protein function.](#)
*A method was developed to generate a complex cDNA expression library...*21st January, 2004
GenVec Inc., 65 West Watkins Mill Road, Gaithersburg, MD 20878, USA.- J Gen Virol. 2003 Dec;84(Pt 12):3417-22.
- [VEGF gene therapy for coronary artery disease and peripheral vascular disease.](#)
*Coronary artery disease (CAD) and peripheral arterial disease (PAD) are...*23rd August, 2003
GenVec Inc., 65 West Watkins Mill Road, Gaithersburg, MD 20878, USA.- Cardiovasc Radiat Med.
2002 Apr-Jun;3(2):114-7.
- [Ligand-directed targeting of genes to the site of disease.](#)
*Coronary artery disease (CAD) and peripheral arterial disease (PAD) are...*19th March, 2003
GenVec, Inc.,- Nat Med. 2003 Jan;9(1):135-9. ([DOI Direct Link](#))

Press Releases on GenVec:

GenVec Reports Third Quarter 2009 Financial Results	5th November, 2009	GenVec, Inc.	<i>-- GenVec was awarded a SBIR grant, valued at approximately \$300,000, from the National Cancer Institute of the NIH to support the research of a new approach to treating</i> <i>GAITHERSBURG, Md., Nov. 5 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC) announced today that SAIC-Frederick, Inc. has signed a contract with GenVec for the development of influenza and HIV</i>
GenVec Signs New Contract to Support HIV and Influenza Vaccine Development	5th November, 2009	GenVec, Inc.	<i>GAITHERSBURG, Md., Nov. 4 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to TNFerade(TM)</i>
FDA Grants Orphan Drug Designation for TNFerade(TM)	4th November, 2009	GenVec, Inc.	<i>GAITHERSBURG, Md., Nov. 3 /PRNewswire-FirstCall/ -- Today GenVec, Inc. (Nasdaq: GNVC) announced that Paul H. Fischer, Ph.D., President and CEO, will present a company overview highlighting recent</i>
GenVec to Present at Merriman Curhan Ford&apos;s Investor Summit 2009	3rd November, 2009	GenVec, Inc.	

[GenVec Announces Third
Quarter 2009 Results
Conference Call](#)

28th October, 2009 GenVec, Inc.

GAITHERSBURG, Md., Oct. 28 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC) announced that it will release financial results for the third quarter ended September 30, 2009 on Thursday, November 5

BioNews Results for GenVec



- [GenVec, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new report released](#)
PR inside: Nov 13 2009 7:44PM Matching: genvec
- [GenVec and SAIC-Frederick to Develop HIV and Influenza Vaccines](#)
BioPharm International: Nov 12 2009 4:16PM Matching: genvec
- [Enzon to sell specialty pharmaceutical business to Sigma-Tau](#)
TradingMarkets: Nov 11 2009 3:35PM Matching: genvec
- [GenVec's TNFerade gets orphan drug designation from US FDA to treat pancreatic cancer](#)
PharmaBiz: Nov 10 2009 10:24AM Matching: genvec
- [Enzon Pharmaceuticals to sell specialty pharmaceutical business to Sigma-Tau](#)
TradingMarkets: Nov 10 2009 8:39PM Matching: genvec
- [FDA Grants Orphan Drug Designation for TNFerade\(TM\)](#)
PR Newswire: Nov 8 2009 5:57PM Matching: genvec
- [Cancer Gene Therapy: GenVec, Inc., Department of Research publishes research in cancer gene therapy](#)
NewsRX: Nov 7 2009 6:17AM Matching: genvec
- [GenVec Signs New Contract to Support HIV and Influenza Vaccine Development](#)
Genetic Engineering News: Nov 6 2009 10:20AM Matching: genvec
- [GenVec Signs New Contract to Support HIV and Influenza Vaccine Development](#)
NewsBlaze: Nov 6 2009 8:20AM Matching: genvec
- [GenVec and SAIC-Frederick signs contract to develop influenza and HIV vaccines](#)
News-Medical.Net: Nov 6 2009 4:57AM Matching: genvec
- [GenVec Reports Third Quarter 2009 Financial Results](#)
Individual.com: Nov 5 2009 11:53PM Matching: genvec
- [GenVec Reports Third Quarter 2009 Financial Results](#)
Montana's News Station: Nov 6 2009 8:58PM Matching: genvec
- [GenVec Reports Third Quarter 2009 Financial Results](#)
KSLA: Nov 6 2009 3:40AM Matching: genvec
- [GenVec Reports Third Quarter 2009 Financial Results](#)
TickerTech.com: Nov 6 2009 12:22AM Matching: genvec
- [GenVec wins orphan drug designation for pancreatic cancer drug](#)
Therapeutics Daily: Nov 6 2009 2:22PM Matching: genvec

GenVec Clinical Trials:



- [TNFerade" Biologic Plus Radiation for Metastatic Melanoma](#)

GenVec Patents:



- 5965358- [Method for assessing the relative purity of viral gene transfer vector stocks](#)
- 6391612- [Vectors, cells, and methods for the production of deleterious adenoviral, herpes viral and adeno-associated viral vectors](#)
- 6440728- [Chimeric vectors comprising a phage packaging site and a portion derived from the genome of a eukaryotic virus](#)
- 6440944- [Methods of administering adenoviral vectors](#)
- 6447995- [Utilizing intrinsic fluorescence to detect adenovirus](#)
- 6455314- [Alternatively targeted adenovirus](#)
- 6458578- [Recombinant cell line produces adenoviral gene products E1 and DEF-A, and/or DEF-B](#)
- 6465253- [Vectors and methods for gene transfer to cells](#)
- 6472176- [Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof](#)
- 6475757- [Plasmids for construction of eukaryotic viral vectors](#)
- 6482616- [RCA-free adenoviral vector system and propagation method](#)
- 6383795- [Efficient purification of adenovirus](#)
- 6329200- [Plasmids for construction of eukaryotic viral vectors](#)
- 6329190- [Targetting adenovirus with use of constrained peptide motifs](#)
- 5965541- [Vectors and methods for gene transfer to cells](#)
- 5994106- [Stocks of recombinant, replication-deficient adenovirus free of replication-competent adenovirus](#)
- 6057155- [Targeting adenovirus with use of constrained peptide motifs](#)
- 6063627- [Methods and vectors for site-specific recombination](#)
- 6113913- [Recombinant adenovirus](#)
- 6127525- [Chimeric adenoviral coat protein and methods of using same](#)
- 6153435- [Nucleic acid that encodes a chimeric adenoviral coat protein](#)
- 6168941- [Method of producing adenoviral vector stocks](#)
- 6225113- [Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene in an at least E4-deficient adenovirus](#)
- 6225289- [Methods and compositions for preserving adenoviral vectors](#)
- 6514943- [Method and composition for preserving viruses](#)
- 6573092- [Method of preparing a eukaryotic viral vector](#)
- 6821775- [Viral vector encoding pigment epithelium-derived factor](#)
- 6861229- [Method of identifying a gene product](#)

- 6908762- [Method of preparing a eukaryotic viral vector](#)
- 6913927- [Non-adenoviral gene product-based complementing cells for adenoviral vectors](#)
- 6939540- [Method of enhancing bone density](#)
- 6951755- [Vectors and methods for gene transfer](#)
- 6998263- [Methods of preparing and using a viral vector library](#)
- 7070930- [Chimeric vectors comprising a phage packaging site and a portion derived from the genome of a eukaryotic virus](#)
- 7141406- [Efficient purification of adenovirus](#)
- 7195896- [Complementary adenoviral vector systems and cell lines](#)
- 6756044- [Antigenic complexes and methods](#)
- 6753321- [Method of modulating neovascularization](#)
- 6740525- [Adenoviral capsid containing chimeric protein IX](#)
- 6576456- [Chimeric adenovirus fiber protein](#)
- 6579522- [Replication deficient adenoviral TNF vector](#)
- 6586226- [Efficient purification of adenovirus](#)
- 6596270- [Methods of administering adenoviral vectors](#)
- 6630299- [Fluorescence detection](#)
- 6649373- [Use of trans-activation and CIS-activation to modulate the persistence of expression of a transgene](#)
- 6649407- [Targeting adenovirus with use of constrained peptide motifs](#)
- 6660521- [Use of trans-activation and CIS-activation to increase the persistence of a transgene in an at least E4-deficient adenovirus](#)
- 6677156- [Non-adenoviral gene product-based complementing cells for adenoviral vectors](#)
- 6682929- [Adenovector complementing cells](#)
- 7214368- [Therapeutic regimen for treating cancer comprising the administration of adenoviral vectors comprising a TNF-.alpha. transgene](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

